Autoimmune Hemolytic Anemia Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Autoimmune Hemolytic Anemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting

National Longitudinal Cohort of Hematological Diseases

Acute Myeloid LeukemiaMultiple MyelomaMyelodysplastic Syndrome+14 more
Institute of Hematology & Blood Diseases Hospital, China2,300 enrolled1 locationNCT04645199
Recruiting
Phase 1

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Relapsed/Refractory Systemic Lupus ErythematosusRelapsed/Refractory Systemic SclerosisRelapsed/Refractory Idiopathic Inflammatory Myopathies+3 more
Beijing Boren Hospital12 enrolled1 locationNCT07361094
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Chronic Lymphocytic Leukemia (CLL)B-cell Acute Lymphoblastic Leukemia (B-ALL)Autoimmune Hemolytic Anemia, AIHA+1 more
Grit Biotechnology28 enrolled2 locationsNCT07205315
Recruiting
Early Phase 1

Safety Study of CC312 in Autoimmune Disease Patients

Rheumatoid Arthritis (RA)Autoimmune Hemolytic AnemiaSystemic Lupus Erythematosus (SLE)+3 more
CytoCares Inc18 enrolled1 locationNCT06888960
Recruiting
Phase 2

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaAutoimmune Hemolytic Anemia+1 more
Gruppo Italiano Malattie EMatologiche dell'Adulto45 enrolled3 locationsNCT05694312
Recruiting

OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia

Immune ThrombocytopeniaAutoimmune Hemolytic AnemiaEvans Syndrome
University Hospital, Bordeaux3,500 enrolled9 locationsNCT05937828